We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It ... Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples. Show more
Ask ADVFN Intelligence (AI)
Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Maravai...
SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators...
Arzneimittelentwicklern und Forschern können ab sofort das CleanScribe-Enzym nutzen, um die Bildung von dsRNA bei der mRNA-Synthese um bis zu 85 % zu reduzieren – ohne Beeinträchtigung von...
Les développeurs de médicaments et les chercheurs peuvent désormais tirer parti de l’enzyme CleanScribe pour réduire la formation d’ARNdb jusqu’à 85 % lors de la synthèse d’ARNm, sans...
Drug developers & researchers can now leverage the CleanScribe enzyme to reduce dsRNA formation by up to 85% in mRNA synthesis without compromising mRNA yield, capping efficiency, or...
Cygnus’ AccuRes Kits to recover, amplify, & quantify remaining host cell DNA during biologic drug manufacturing to produce safer, more stable vaccines, therapies, and more Cygnus Technologies...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.65 | -21.625163827 | 7.63 | 8.17 | 5.82 | 1357674 | 7.72294525 | CS |
| 4 | -1.65 | -21.625163827 | 7.63 | 8.535 | 5.82 | 1315134 | 7.72276945 | CS |
| 12 | -2.44 | -28.9786223278 | 8.42 | 9.95 | 5.82 | 1819715 | 8.58390107 | CS |
| 26 | -3.11 | -34.2134213421 | 9.09 | 11.555 | 5.82 | 1894464 | 8.67896431 | CS |
| 52 | -0.79 | -11.6691285081 | 6.77 | 11.555 | 4.52 | 2225407 | 7.57328869 | CS |
| 156 | -30.52 | -83.6164383562 | 36.5 | 46.29 | 4.52 | 2040941 | 15.6342643 | CS |
| 260 | -25.13 | -80.7778849245 | 31.11 | 63.55 | 4.52 | 1902555 | 20.03572544 | CS |
Monksdream
8 months ago
Monksdream
8 months ago
crudeoil24
4 years ago
crudeoil24
4 years ago
crudeoil24
4 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
